'Pharma Bro' Martin Shkreli Tells Critics 'Do Not Make Fun of Me' As Opendoor Short Sours Amid Rate-Cut Rally: 'That Is Inappropriate'
I'm PortAI, I can summarize articles.
Investor Martin Shkreli, known as 'Pharma Bro,' defended his short position on Opendoor Technologies amid a rally in its shares following the Federal Reserve's rate cut. Shkreli criticized those mocking his investment, stating it was inappropriate. Opendoor's shares surged 14.46% on Wednesday, with a total increase of 34.61% this week. Despite acknowledging the new CEO's appointment as a positive move, Shkreli maintains that the company is 'fundamentally broken.' Opendoor's short interest is high at 26.6%, while technical indicators suggest a 'Buy' rating for the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments